Michigan clinical drug trial

Study the incidence and outcome of adverse events such as osteoporosis, splenomegaly, cytogenetic abnormalities, myelodysplastic syndrome, and leukemia. Evaluate growth and development and hematologic parameters. Monitor for clinically significant changes in primary treatme The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at months corrected age Infants born prior to July 1, were seen at months corrected age.

Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment i. Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.

This clinical trial studies cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.

The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme Recombinant Human Alpha-L-Iduronidase , or other treatment modalities.

The objectives of the Registry are: To evaluate the long The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary objectives of the Registry are: To enhance the understanding of the variability, progression, and natural history of Fab The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not.

The objectives of the Registry are: To enhance understanding of the This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis.

Lymphocytes are a type of white blood cell that fights infections. Normally, the body keeps a precise balance in which lymphocyte growth is matched by lymphocyte death.

People with constantly enlarged lymph nodes or spleen, along with autoimmune disease, immunodeficiency, lymphoma, or other immune problems affecting lymphocytes may have an abnormality of the immune system i The main purpose of the Product Performance Report formerly referred to as System Longevity Study is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine. Recently added acute cases enrollment that meets criteria to the protocol.

Also added Fibroscans to the protocol that will be completed at baseline and follow-up on chronic subjects. The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status.

Clair Shores total 2 new 60 updated St. Joseph total 2 new 32 updated St. Louis 45 total 2 new 1 updated Sterling Heights total 2 new updated Stevensville total 2 new 32 updated Traverse City total 2 new 37 updated Trenton 87 total 2 new 20 updated Troy total 2 new updated Warren total 2 new 80 updated West Bloomfield total 2 new 95 updated West Branch total 2 new 33 updated Wyoming total 2 new 98 updated Ypsilanti 1, total 2 new updated.

Volunteer to support the development of new treatments. Sign up as a volunteer. Toledo Clinic Cancer Centers - Monroe. Saint Joseph Mercy Oakland. Saint John Macomb-Oakland Hospital. Karmanos Cancer Institute. Saint Joseph Mercy Hospital. Weisberg Cancer Treatment Center. Saint Mary Mercy Hospital. William Beaumont Hospital-Royal Oak. Saint Mary's of Michigan. Sparrow Clinical Research Institute. Barbara Ann Karmanos Cancer Institute. Michigan State University.

Sparrow Hospital. Spectrum Health Reed City Hospital. Marie Yeager Cancer Center. C S Mott Children's Hospital. Kalamazoo Center for Medical Studies. Saint Joseph Mercy Cancer Center. Sparrow Regional Cancer Center.